Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26: 381–389.

    Article  CAS  Google Scholar 

  2. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119: 3256–3262.

    Article  CAS  Google Scholar 

  3. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T . Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078–3085.

    Article  CAS  Google Scholar 

  4. Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR, Kröger N . Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol 2009; 37: 135–142.

    Article  CAS  Google Scholar 

  5. Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E et al. Evaluation of BM cytomorphology after allo-SCT in patients with MDS. Bone Marrow Transplant 2013; 48: 465–466.

    Article  CAS  Google Scholar 

  6. Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T et al. Evaluation of BM cytomorphology after allo-SCT in patients with AML. Bone Marrow Transplant 2012; 47: 1538–1544.

    Article  CAS  Google Scholar 

  7. Chantepie SP, Salaun V, Parienti JJ, Truquet F, Macro M, Cheze S et al. Hematogones: a new prognostic factor for acute myeloblastic leukemia. Blood 2011; 117: 1315–1318.

    Article  CAS  Google Scholar 

  8. Honebrink T, Dayton V, Burke MJ, Larsen K, Cao Q, Brunstein C et al. Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. Biol Blood Marrow Transplant 2012; 18: 930–936.

    Article  Google Scholar 

  9. Shima T, Miyamoto T, Kikushige Y, Mori Y, Kamezaki K, Takase K et al. Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation. Blood 2012; 121: 840–848.

    Article  Google Scholar 

  10. Christopeit M, Schütte V, Theurich S, Weber T, Grothe W, Behre G . Rituximab reduces the incidence of acute graft-versus-host disease. Blood 2009; 113: 3130–3131.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to U Bacher.

Ethics declarations

Competing interests

TH declares part ownership of the MLL Munich Leukemia Laboratory GmbH. The remaining authors declare no conflict of interest.

Additional information

Author contributions

MC and UB designed the study, analysed data and wrote the manuscript. AH collected and analysed data; MB, TZ, FA, CH, TH, CB and NK analysed data. FA, CB and NK contributed to recruiting patients. All authors contributed to writing of the manuscript and the interpretation of data, and agreed to the final version of the manuscript. Data in this manuscript were in part assembled during the thesis (‘Dr med.’) work of AH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Christopeit, M., Heiland, A., Binder, M. et al. Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML. Bone Marrow Transplant 48, 1257–1259 (2013). https://doi.org/10.1038/bmt.2013.34

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.34

This article is cited by

Search

Quick links